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14TexRace and Socioeconomic Status Influence Outcomes
of Unrelated Donor Hematopoietic Cell
Transplantation
K. Scott Baker,1 Stella M. Davies,2 Navneet S. Majhail,3,4 Anna Hassebroek,4 John P. Klein,5
Karen K. Ballen,6 Carolyn L. Bigelow,7 Haydar A. Frangoul,8 Cheryl L. Hardy,7
Christopher Bredeson,9 Jason Dehn,10 Debra Friedman,8 Theresa Hahn,11 Gregory Hale,12
Hillard M. Lazarus,13 C. F. LeMaistre,14 Fausto Loberiza,15 Dipnarine Maharaj,16
Philip McCarthy,11 Michelle Setterholm,10 Stephen Spellman,10 Michael Trigg,17
Richard T. Maziarz,18 Galen Switzer,19 Stephanie J. Lee,1 J. Douglas Rizzo5Success of hematopoietic cell transplantation (HCT) can vary by race, but the impact of socioeconomic
status (SES) is not known. To evaluate the role of race and SES, we studied 6207 unrelated-donor myeloa-
blative (MA) HCTrecipients transplanted between 1995 and 2004 for acute or chronic leukemia or myelo-
dysplastic syndrome (MDS). Patients were reported by transplant center to be White (n 5 5253), African
American (n5 368), Asian/Pacific-Islander (n5 141), or Hispanic (n5 445). Patient income was estimated
from residential zip code at time of HCT. Cox regression analysis adjusting for other significant factors
showed that African American (but not Asian or Hispanic) recipients had worse overall survival (OS) (rel-
ative-risk [RR] 1.47; 95% confidence interval [CI] 1.29-1.68, P\ .001) compared to Whites. Treatment-
related mortality (TRM) was higher in African Americans (RR 1.56; 95% CI 1.34-1.83, P\ .001) and in
Hispanics (RR 1.30; 95% CI 1.11-1.51, P 5 .001). Across all racial groups, patients with median incomes in
the lowest quartile (\$34,700) had worse OS (RR 1.15; 95% CI 1.04-1.26, P 5 .005) and higher risks of
TRM (RR 1.21; 1.07-1.36, P 5 .002). Inferior outcomes among African Americans are not fully explained
by transplant-related factors or SES. Potential other mechanisms such as genetic polymorphisms that have
an impact on drug metabolism or unmeasured comorbidities, socioeconomic factors, and health behaviors
may be important. Low SES, regardless of race, has a negative impact on unrelated donor HCToutcomes.
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noma of the breast [4,5], colon [4], oral cancers [5],
acute myelogenous leukemia (AML) [6], and Hodgkin
lymphoma (HL) [7]. Possible explanations for these
differences might include cultural attitudes in seeking
medical care, treatment variability, as well as potential
lack of access to primary care (and subsequently de-
layed diagnosis). SEShas also been considered as a con-
tributing factor to racial differences in outcome for
cancer patients. However, even controlling for stage
of disease, most studies suggest that SES alone cannot
explain a racial difference in outcome [8-11].
Until recently, differences in the outcome of ethnic
minorities undergoingHCThave not been described in
detail. A previous study from the Center for Interna-
tional Blood and Marrow Transplant Research
(CIBMTR) compared trends in survival rates in ethnic
minorities after HCT from human leukocyte antigen
(HLA)-identical sibling donors [12]. The study found
that Hispanics had lower 1-year and 3-year survival
rates compared with Whites, whereas no differences
were identified betweenWhites and African Americans
or Asians [12]. A follow-up study found that the de-
crease in overall survival (OS) amongHispanicswas pri-
marily related to higher risks of treatment failure (death
or relapse) and higher risk of overall mortality [13].
Mielcarek et al. [14], in a cohort of sibling and unrelated
donor HCT recipients, have also reported a signifi-
cantly higher risk ofmortality amongAfrican American
HCT recipients compared with White recipients.
Increased genetic disparity at both the HLA locus
and at minor transplantation antigens may have an im-
portant influence on the outcome of HCT. In addition,
polymorphism in cytokine genes can also influence
HCT outcomes [15,16]. These genetic factors might
be expected to vary between ethnicities, and may con-
tribute to disparate outcomes. A previous CIBMTR
study among recipients of sibling donor HCT, per-
formed in collaboration with transplant registries in
Japan, Scandinavia, and Ireland, showed reduced risk
of graft-versus-host disease (GVHD) in the less geneti-
cally diverse Japanese and Scandinavian populations
compared withWhite-American and African-American
populations [17]. However, the risks of GVHD were
similar between the Irish and the White-American and
African-American populations. The study concluded
that the etiology of ethnic disparities in GVHD are
complex, and may include differences in HLA and
minor antigen diversity, frequencies of cytokine poly-
morphisms, and nongenetic variables such as diet, envi-
ronment, and differences in GVHD diagnosis and
management.
Available studies investigating race in HCT are
largely limited to recipients of sibling donor HCT
and suggest important and as yet unexplained racial dif-
ferences. Also, the impact of sociocultural factors on
outcomes of HCT has not been well described [14].In the current study, we explore the association of race
and SES with outcomes for unrelated HCT recipients.METHODS
Data Source
The CIBMTR is a research affiliation of the Inter-
national Bone Marrow Transplant Registry (IBMTR),
Autologous Blood and Marrow Transplant Registry
(ABMTR), and the National Marrow Donor Program
(NMDP) that comprises a voluntary working group of
more than 450 transplantation centers worldwide that
contribute detailed data on consecutive allogeneic and
autologous hematopoietic SCT to a Statistical Center
at theMedical College ofWisconsin inMilwaukee and
the NMDPCoordinating Center inMinneapolis. Par-
ticipating centers are required to report all transplants
consecutively; compliance is monitored by on-site au-
dits. Patients are followed longitudinally, with yearly
follow-up. The overall follow-up of the cohort was
100% at 1 year and 95% overall, and did not differ sig-
nificantly among the various racial categories. Com-
puterized checks for errors, physicians’ review of
submitted data, and on-site audits of participating
centers ensure data quality. Observational studies con-
ducted by the CIBMTR are done so with a waiver of
informed consent and in compliance with HIPAA
regulations as determined by the institutional review
board and the Privacy Officer of the Medical College
of Wisconsin.Participants
The study included patients who received an unre-
lated donor allogeneicHCTwith amyeloablative (MA)
preparative regimen using either a bone marrow (BM)
or peripheral blood stem cell (PBSC) source for AML,
acute lymphoblastic leukemia (ALL), chronicmyeloge-
nous leukemia (CML), or myelodysplastic syndrome
(MDS) between 1995 and 2004. Only patients trans-
planted in a center in the United States and with avail-
able residential postal zip codes were eligible for this
analysis; 8 patients with missing zip code information
were excluded. Patients who received unrelated umbil-
ical cord blood (UCB) as donor source (n5 163) or had
previously undergone HCT (n 5 516) were also ex-
cluded from the study. Information about patient race
was reported by transplant centers and was categorized
according to the U.S. Office of Management and Bud-
get classification asWhite, AfricanAmerican,Hispanic,
orAsian/Pacific-Islander. Patient incomewasestimated
by the mean household income of their zip code from
the 2004 U.S. Census. Distances between the center
of a patient’s residence and the transplant center were
approximated using the Haversine approximation on
the latitude and longitude of the zip code [18]. The
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income and location data from the zip code.
All surviving recipients included in this analysis
were retrospectively contacted and they provided in-
formed consent for participation in the NMDP re-
search program. Informed consent was waived by the
NMDP institutional review board for all deceased
recipients. Approximately 10% of surviving patients
would not provide consent for use of research data.
To adjust for the potential bias introduced by exclu-
sion of nonconsenting surviving patients, a corrective
action plan modeling process randomly excluded ap-
propriately the same percentage of deceased patients
(n 5 532) using a biased coin randomization with ex-
clusion probabilities based on characteristics associ-
ated with not providing consent for use of the data in
survivors [20]. The final study cohort consisted of
6207 patients (Table 1). The followup completeness
index from time of HCT, which is the ratio of total
observed person-time and the potential person-time
of followup in a study [21], was 98% at 1 year and
90% at 5 years post-HCT.Outcomes and Study Definitions
The primary objective of this study was to deter-
mine the impact of race and household income on
OS, disease-free survival (DFS), relapse, and treat-
ment-related mortality (TRM). DFS was defined as
survival in complete remission after HCT. For OS,
death from any cause was considered an event. Relapse
was defined as disease recurrence at any site. TRMwas
defined as death in complete remission. OS, DFS, re-
lapse, and TRM were assessed from the date of
HCT. All patients were assessed for acute and chronic
GVHD (aGVHD, cGVHD) by standard criteria
[22,23].
Based on previous CIBMTR publications of dis-
ease specific outcomes and differential outcomes in
ethnic minorities with related donor transplants
[12,13,24-27], disease status was classified as early,
intermediate, or advanced. Early disease included
AML and ALL in first complete remission, CML in
first chronic phase, and MDS with refractory anemia
(RA) or refractory anemia with ringed sideroblasts
(RARS). AML and ALL in second or greater remission
or CML in accelerated phase or second or greater
chronic phase was categorized as intermediate disease.
Patients with advanced disease had AML and ALL in
relapse or primary induction failure, CML in blast
phase, or MDS with refractory anemia with excess
blasts (RAEB) or excess blasts in transformation.
The NMDP classification of HLAmatching status
that allows adequate adjustment for donor-recipient
HLA compatibility while accounting for best available
resolution of typing was used to categorize HLA
matching status as well-matched, partially matched,or mismatched [25]. Briefly, well-matched patients
had no identified mismatches at HLA-A, -B, -C, and
-DRB1 with low/intermediate- or high-resolution
data available at HLA-A,-B and high-resolution
-DRB1. Partially matched patients had a single locus
mismatch at any of the 4 loci and/or missing HLA-C
data. Mismatched patients had 2 or more allele or
antigen mismatches.Statistical Analysis
Patient, disease, and HCT-related characteristics
were compared by chi-square statistic for categoric
variables and the Kruskal-Wallis test for continuous
variables. Probabilities of OS and DFS were calculated
using the Kaplan-Meier method. Probabilities of
TRM, relapse, neutrophil engraftment, and aGVHD
and cGVHD were calculated by the cumulative-inci-
dence function method.
To adjust for differences in baseline characteris-
tics, multivariate Cox proportional-hazards regression
models were used. Household income was correlated
with outcome using a series of threshold models in
the Cox model framework. These models were then
constructed to find cut off points that best described
the impact of income on outcome by picking themodel
with the largest partial likelihood [28]. Associations
between each outcome and potential prognostic vari-
ables (Table 2) were evaluated using a stepwise
approach. Variables significantly associated with each
outcome event (P \ .05) were included as covariate
factors in subsequent comparisons. The assumption
of proportional hazards was tested in a time-dependent
covariate fashion. Results were expressed as relative
risks (RR) of each outcome. The models for OS,
DFS, relapse, and TRMwere stratified on a Karnofsky
Score. The models for aGVHD and cGVHD were
stratified on patient age. For engraftment, logistic re-
gression was used to model the chance of neutrophil
recovery at day 28. A similar analysis to the Cox anal-
ysis was performed; the results are reported as the odds
in favor of engraftment. For each outcome the main
effects of race and household income were tested
for an interaction with each of the other covariates
(including sex) that entered the models. This was
done for each outcome. None of these were found to
be significant at a 5% significance level.
The analysis found a significant transplant center
effect using a random effects test on the survival times
[29]. To adjust for center, a stepwise regression model
was used that included at each step the main effects as
well as all covariates adjusted for in the model for the
given event. The centers found to enter and stay in
the model at a 5% significance level were included in
the final model.
To examine the robustness of our results in
patients with high-resolution HLA typing, a subset
Table 1. Characteristics of Patients Transplanted at U.S. Centers Who Received Unrelated Donor Myeloablative Hematopoietic
Cell Transplants for AML, ALL, CML, and MDS from 1995-2004 by Race
Variable White N (%) African-American N (%) Asian/Pacific Islander N (%) Hispanic N (%) P Value
Number of patients 5253 368 141 445
Number of centers 119 87 40 80
Age, median (range), years 35 (<1-70) 25 (<1-58) 30 (<1-56) 22 (<1-62) <.001
Age at transplant, years <.001
<10 535 (10) 64 (17) 22 (16) 99 (22)
10-19 683 (13) 83 (23) 24 (17) 92 (21)
20-29 846 (16) 70 (19) 23 (16) 97 (22)
30-39 1091 (21) 65 (18) 35 (25) 81 (18)
40-49 1291 (25) 69 (19) 28 (20) 54 (12)
$50 807 (15) 17 (5) 9 (6) 22 (5)
Male sex 2979 (57) 214 (58) 83 (59) 270 (61) .39
Median income, 2000* $44,776 $36,275 $50,991 $40,111 <.001
Missing 524 39 12 60
Distance to transplant center <.001
<17 miles 1109 (21) 159 (43) 64 (46) 181 (41)
17-55 miles 1321 (25) 69 (19) 34 (24) 113 (25)
55-150 miles 1398 (27) 76 (21) 17 (12) 74 (17)
>150 miles 1364 (26) 62 (17) 23 (16) 74 (17)
Missing ZIP code 61 (1) 2 (<1) 3 (2) 3 (<1)
Karnofsky status .06
$90 3574 (68) 268 (73) 92 (65) 323 (73)
<90 1352 (26) 75 (20) 43 (30) 94 (21)
Missing 327 (6) 25 (7) 6 (4) 28 (6)
Comorbid conditions .01
0-1 conditions 4792 (91) 342 (93) 136 (96) 420 (94)
$2 conditions 461 (9) 26 (7) 5 (4) 25 (6)
Body mass index, kg/m2 25 (11-44) 24 (11-42) 21 (13-41) 23 (11-44) <.001
Disease <.001
AML 1825 (35) 108 (29) 39 (28) 98 (22)
ALL 1261 (24) 90 (24) 48 (34) 193 (43)
CML 1531 (29) 153 (42) 39 (28) 121 (27)
MDS 636 (12) 17 (5) 15 (11) 33 (7)
Disease status at transplant <.001
Early 2067 (39) 120 (33) 47 (33) 158 (36)
Intermediate 1528 (29) 163 (44) 49 (35) 182 (41)
Advanced 1490 (28) 80 (22) 38 (27) 99 (22)
Unknown 168 (3) 5 (1) 7 (5) 6 (1)
HLA match status <.001
Well matched 2421 (46) 81 (22) 41 (29) 122 (27)
Partially matched 1939 (37) 135 (37) 48 (34) 160 (36)
Mismatched 893 (17) 152 (41) 52 (37) 163 (37)
Race match (donor/recipient) <.001
Match 4138 (78) 251 (68) 116 (82) 211 (47)
Mismatch 431 (9) 110 (30) 21 (15) 205 (46)
Unknown 684 (13) 7 (2) 4 (3) 29 (7)
Donor age, median (range), years 35 (18-61) 36 (19-60) 34 (18-59) 34 (19-59) .09
Age at transplant, years .11
18-19 38 (1) 3 (1) 2 (1) 5 (1)
20-29 1475 (28) 102 (28) 46 (33) 125 (28)
30-39 2029 (39) 115 (31) 51 (36) 184 (41)
40-49 1354 (26) 120 (33) 32 (23) 100 (22)
$ 50 357 (7) 28 (8) 10 (7) 31 (7)
Sex match (donor/recipient) <.001
Male/male 2050 (39) 103 (28) 42 (30) 146 (33)
Male/female 1262 (24) 72 (20) 34 (24) 81 (18)
Female/male 929 (18) 111 (30) 41 (29) 124 (28)
Female/female 1012 (19) 82 (22) 24 (17) 94 (21)
CMV match (donor/recipient) <.001
Negative/negative 1945 (37) 63 (17) 8 (6) 59 (13)
Negative/positive 1514 (29) 94 (26) 36 (26) 131 (29)
Positive/negative 820 (16) 69 (19) 20 (14) 72 (16)
Positive/positive 887 (17) 133 (36) 75 (53) 176 (40)
Unknown 87 (2) 9 (2) 2 (1) 7 (2)
Year of transplant <.001
1995-1999 2716 (52) 181 (49) 71 (50) 177 (40)
2000-2004 2537 (48) 187 (51) 70 (50) 268 (60)
Conditioning regimen <.001
Bu + Cy ± other 1066 (20) 50 (14) 16 (11) 52 (12)
Cy + TBI ± other 3720 (71) 279 (76) 120 (85) 336 (76)
TBI ± other 183 (3) 10 (3) 5 (4) 26 (6)
(Continued )
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Table 1. (Continued )
Variable White N (%) African-American N (%) Asian/Pacific Islander N (%) Hispanic N (%) P Value
Other 284 (6) 29 (8) 0 31 (7)
GVHD prophylaxis†
CsA + MTX ± other 2681 (51) 167 (45) 86 (61) 187 (42)
Tacrolimus + MTX ± other 1200 (23) 85 (23) 25 (18) 144 (32)
T cell depletion ± other 941 (18) 88 (24) 16 (11) 73 (16)
CsA or tacrolimus ± other 371 (7) 27 (7) 13 (9) 37 (8)
Other 60 (1) 1 (<1) 1 (<1) 4 (<1)
Graft type .02
Bone marrow 4298 (82) 321 (87) 109 (77) 358 (80)
Peripheral blood 955 (18) 47 (13) 32 (23) 87 (20)
Infused cell dose†
BM >2108 2659 (62) 173 (54) 61 (56) 219 (61)
BM #2108 1601 (37) 146 (45) 43 (39) 139 (39)
BM missing 38 (<1) 2 (<1) 5 (5) 0
PB >5108 592 (62) 28 (60) 18 (56) 62 (71)
PB #5108 292 (31) 19 (40) 12 (38) 22 (25)
PB missing 71 (7) 0 2 (6) 3 (3)
Time from diagnosis to transplant, median
(range), months
10 (1-309) 15 (2-273) 13 (2-179) 16 (2-170) <.001
Donor search time, median (range), months‡
Diagnosis to preliminary search 3 (<1-303) 5 (<1-268) 5 (<1-134) 5 (<1-164) <.001
Preliminary search to formal search <1 (<1-116) <1 (<1-51) <1 (<1-85) <1 (<1-41) .03
Formal search to transplant 3 (<1-125) 4 (1-91) 3 (<1-89) 4 (1-58) <.001
Follow-up of survivors, median (range), months 66 (3-138) 48 (3-130) 64 (11-127) 48 (11-132) <.001
AML indicates acute myelogenous leukemia; ALL, acute lymphoblastic leukemia; MDS, myelodysplastic syndrome; CML, chronic myelogenous leukemia;
HLA, human leukocyte antigen; CMV, cytomegalovirus; Cy, cyclophosphamide; Bu, busulfan; TBI, total body radiation; CsA, cyclosporine; MTX, meth-
otrexate; GVHD, graft-versus-host disease; BM, bone marrow; PB, peripheral blood.
*Based on 2004 Census tract data linking income to residential ZIP code.
†Univariate comparison not done because of small cell counts.
‡Preliminary search provides a list of potential donors at a given time but does not initiate contact with no further testing of the donors. If the transplant
center decides to proceed with unrelated donor HCT, formal search is initiated on behalf of the patient. This includes confirmatory HLA typing of the
patient and donor and confirmation of the availability of the donor for obtaining hematopoietic stem cells.
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the HLA-A, -B, -C, and -DRB1 loci (n 5 3864) was
performed for the endpoints of OS, DFS, relapse,
and TRM.
All P-values are 2 sided and, to account for multi-
ple comparisons, a value of P\.01 was considered to
be significant. Analyses were performed using SAS
software, version 9.1 (SAS Institute, Cary, NC).RESULTS
Patient Characteristics
Table 1 describes patient, disease, and treatment
characteristics by race. Asian/Pacific Islanders had
the highest median household income ($50,991)
whereas African Americans had the lowest ($36,275).
Table 3 describes our cohort’s characteristics by
socioeconomic status. A greater proportion of
African Americans (45%) belonged to the lowest
income quartile (median income \$34,700), com-
pared to Hispanics (35%), Whites (21%), or Asian/
Pacific-Islanders (9%).Race and Outcomes
In univariate analyses, African-Americans had the
lowest probability of OS andDFS and the highest ratesof TRM (Figures 1 and 2). Cumulative incidence of
relapse was similar among all 4 racial groups.
In a multivariate analysis adjusting for other prog-
nostic variables (including annual income), African
American race was associated with significantly worse
OS and DFS and higher TRM than Whites (Table 4).
Risk of TRM was also increased in Hispanics, but OS
and DFS was comparable. The risk for relapse was sim-
ilar among the 4 racial groups. Race had no impact on
neutrophil engraftment or risks of grades 2-4 aGVHD.
The RR of grade III-IV aGVHD was slightly higher in
African-Americans (1.26 [1.03-1.54], P5NS), whereas
that for cGVHDwas higher in African-Americans (1.34
[1.10-1.63], P5 .003) and Hispanics (1.25 [1.06-1.48],
P 5 .008). A subset analysis limited to 3864 recipients
with allele-level typing at the HLA-A, -B, -C, and
-DRB1 loci showed risks for OS, DFS, relapse, and
TRMsimilar to those observed in analyses that included
the whole cohort (data not shown).
Income and Outcomes
Patients with amedian annual income in the lowest
quartile (\$37,400) had lower probability of OS and
DFS and higher rates of TRM (Figures 3 and 4).
Relapse was similar in all income categories.
In a multivariate analysis adjusting for other prog-
nostic variables (including race), patients with incomes
in the lowest quartile (\$37,400) had significantly
Table 2. Variables Tested in Multivariate Analysis
Main effect variable
Race/ethnicity: White* versus African-American versus Asian/Pacific-
Islander versus Hispanic
Patient-related variables
Age:# 10* years versus 11-20 years versus 21-30 years versus 31-40 years
versus 41-50 years versus >50 years
Sex: Male* versus female
Karnofsky performance status at transplant: <90% versus $90%*
versus missing
Median income: above* versus below median versus missing
Comorbid medical conditions: 0-1* versus $ 2 comorbidities
Distance to transplant center: above* versus below median versus missing
Disease-related variables
Disease: AML* versus ALL versus CML versus MDS
Disease status: early* versus intermediate versus advanced disease
Time from diagnosis to transplant: continuous
Transplant-related variables
Source of stem cells: bone marrow* versus peripheral blood
HLA match: well-matched* versus partially matched versus mismatched
Donor age: 18-20* years versus 21-30 years versus 31-40 years versus
41-50 years versus >50 years
Donor-recipient sex match: F-M versus M-F versus M-M* versus F-F
Donor-recipient CMV status: 2/2* versus 2/+ versus +/2 versus +/+
versus unknown
Year of transplant: 1995-1999 versus 2000-2004*
Conditioning regimen: Bu + Cy ± others versus Cy + TBI ± others * versus
TBI ± others versus other
Donor-recipient race match: same ethnicity* versus disparate ethnicity
versus unknown
Infused cell dose: #2108 versus >2108* nucleated cells/kg for bone
marrow and #5 x 108 versus >5108* nucleated cells/kg for
peripheral blood
Donor search time (months) (diagnosis to preliminary search, preliminary
search to formal search and formal search to transplant): above*
versus below median
AML indicates acutemyelogenous leukemia;ALL, acute lymphoblastic leuke-
mia;MDS,myelodysplastic syndrome;CML, chronicmyelogenous leukemia;
HLA, human leukocyte antigen; F, female; M, male; CMV, cytomegalovirus;
Cy, cyclophosphamide; Bu, busulfan; TBI, total body radiation.
*Reference group.
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(RR 1.21 [1.07-1.36], P 5 .002) than those with
incomes in the highest quartile (.$56,000) (Table 4).
Household income had no impact on risks of DFS,
relapse, aGVHDor cGVHD. A subset analysis limited
to patients with allele-level typing again showed risks
similar to those observed for the whole cohort (data
not shown).
Causes of Death
For the whole cohort, the principal causes of death
included recurrence of primary malignancy (25%),
infection (20%), organ failure (18%), aGVHD or
cGVHD (14%), and interstitial pneumonitis (12%),
and these did not differ when compared by race or
SES. Table 5 describes the causes of death within
and after 100 days following transplantation by race
and SES.DISCUSSION
Our study shows notably decreased survival in
African-American unrelated donor HCT recipientscompared with White, Asian, and Hispanic recipients,
despite adjustment in multivariate analysis for HLA
matching, disease status, family income, and other
variables likely to influence outcome. Reduced survival
was because of increased TRM in African-American
recipients with no increased risk of aGVHD or relapse
detected. There are many possible reasons for reduced
survival in African-American HCT recipients, includ-
ing biology (e.g., polymorphism at non-HLA loci), ac-
cess to care including post-HCT follow-up, disparities
in treatment or follow-up practices, environmental
factors (that may also be influenced by SES), and
health behaviors. Additionally, there were several dif-
ferences in baseline patient characteristics between
the groups. However, the analysis was adjusted for
the potential patient, disease, and center characteris-
tics that differ between the groups. If the survival dif-
ferences found were caused by these baseline
differences, this adjustment would actually tend to
lower, not increase, the reported effect of race. Addi-
tionally, there was no evidence of an interaction be-
tween these factors in the model with race or income.
Biologic factors, such as increasedgenetic polymor-
phism in African-American recipients, could impact
outcomes. It is clear that improved HLAmatching im-
proves HCT outcome, and it is known that there is
greater diversity at HLA loci in the African-American
population compared with other races and ethnicities
[17]. In our study, however, outcomes were inferior in
African-American recipients even after adjustment for
HLAmatchingwith the donor. This raises the possibil-
ity that genetic variation at other locimay bemodifying
outcomes. At a population level, African Americans
show significantly higher levels of nucleotide heterozy-
gosity compared with Americans of European origin
[30]. Polymorphisms that modify expression of cyto-
kine genes have been shown to modify a number of
HCT endpoints, and it is possible that less favorable al-
leles may occur more frequently in African-American
HCT recipients [12,15,16,31]. In agreement with our
study, reduced graft survival andOShave been reported
in African-American recipients of renal transplants
[32], with a similar finding reported after liver trans-
plantation in African- American recipients secondary
to chronic rejection [33]. In cancer patients, pharmaco-
genetic variation in drugmetabolism has been reported
for cyclophosphamide (Cy), methotrexate (MTX), and
busulfan (Bu), all of which had an impact onHCT out-
comes [34-38]. Frequencies of many pharmacogenetic
variants influencing metabolism of these drugs vary
by race, and future pharmacogenetic studies, which
would likely need to bemulticenter to achieve adequate
sample size, might determine whether this is an impor-
tant variable, as personalized drug dosing might im-
prove outcomes [39-41].
Racial disparities exist in health care access and
outcomes and are related to SES. It has been reported
Table 3. Characteristics of Patients Transplanted at U.S. Centers Who Received Unrelated Donor Myeloablative Hematopoietic
Cell Transplants for AML, ALL, CML, and MDS from 1995-2004 by Socioeconomic Status
Median Income*
Variable <$34,700 N (%) $34,700-43,600 N (%) $43,600-56,300 N (%) >$56,300 N (%) P Value
Number of patients 1414 1541 1517 1559
Number of centers 107 116 111 107
Age, median (range), years 31 (<1-65) 33 (<1-67) 34 (<1-70) 35 (<1-67) <.001
Age at transplant, years <.001
<10 172 (12) 189 (12) 167 (11) 177 (11)
10-19 234 (17) 215 (14) 216 (14) 191 (12)
20-29 264 (19) 264 (17) 245 (16) 233 (15)
30-39 298 (21) 316 (21) 303 (20) 316 (20)
40-49 293 (21) 351 (23) 370 (24) 388 (25)
$50 153 (11) 206 (13) 216 (14) 254 (16)
Male sex 814 (58) 889 (58) 849 (56) 885 (57) .76
Race <.001
White 1091 (77) 1308 (85) 1321 (87) 1383 (89)
African-American 160 (11) 89 (6) 53 (3) 54 (3)
Asian/Pacific-Islander 12 (1) 37 (2) 28 (2) 57 (4)
Hispanic 151 (11) 107 (7) 115 (8) 65 (4)
Distance to
transplant center
<.001
<20 miles 274 (19) 312 (20) 414 (27) 500 (32)
20-70 miles 157 (11) 331 (21) 464 (31) 558 (36)
70-175 miles 509 (36) 505 (33) 353 (23) 169 (11)
>175 miles 474 (34) 393 (26) 286 (19) 332 (21)
Karnofsky status .29
$90 959 (68) 1070 (69) 1047 (69) 1063 (68)
<90 378 (27) 386 (25) 371 (24) 384 (25)
Missing 77 (5) 85 (6) 99 (7) 112 (7)
Comorbid conditions .21
0-1 conditions 1292 (91) 1414 (92) 1378 (91) 1448 (93)
$ 2 conditions 122 (9) 127 (8) 139 (9) 111 (7)
Body mass index, kg/m2 24 (11-44) 25 (12-44) 25 (13-44) 24 (13-43) .008
Disease .91
AML 471 (33) 508 (33) 511 (34) 520 (33)
ALL 382 (27) 390 (25) 384 (25) 391 (25)
CML 417 (29) 461 (30) 443 (29) 467 (30)
MDS 144 (10) 182 (12) 179 (12) 181 (12)
Disease status at transplant .37
Early 515 (36) 588 (38) 602 (40) 608 (39)
Intermediate 464 (33) 482 (31) 445 (29) 477 (31)
Advanced 403 (29) 424 (28) 417 (27) 424 (27)
Unknown 32 (2) 47 (3) 53 (3) 50 (3)
HLA match status .009
Well matched 582 (41) 630 (41) 675 (44) 705 (45)
Partially matched 523 (37) 584 (38) 531 (35) 586 (38)
Mismatched 309 (22) 327 (21) 311 (21) 268 (17)
Race match
(donor/recipient)
.54
Match 187 (13) 180 (12) 188 (12) 190 (12)
Mismatch 1069 (76) 1184 (77) 1163 (77) 1168 (75)
Unknown 158 (11) 177 (11) 166 (11) 201 (13)
Donor age, median
(range), years
35 (18-60) 35 (18-60) 36 (18-60) 35 (18-61) .011
Sex match (donor/
recipient)
.89
Male/male 535 (38) 573 (37) 573 (38) 592 (38)
Male/female 321 (23) 354 (23) 364 (24) 379 (24)
Female/male 279 (20) 316 (21) 276 (18) 293 (19)
Female/female 279 (20) 298 (19) 304 (20) 295 (19)
CMV match (donor/
recipient)
.002
Negative/negative 417 (29) 511 (33) 543 (36) 546 (35)
Negative/positive 456 (32) 412 (27) 416 (27) 434 (28)
Positive/negative 207 (15) 250 (16) 228 (15) 267 (17)
Positive/positive 308 (22) 342 (22) 304 (20) 288 (18)
Unknown 26 (2) 26 (2) 26 (2) 24 (2)
Year of transplant .19
1995-1999 741 (52) 761 (49) 783 (52) 766 (49)
2000-2004 673 (48) 780 (51) 734 (48) 793 (51)
(Continued )
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Median Income*
Variable <$34,700 N (%) $34,700-43,600 N (%) $43,600-56,300 N (%) >$56,300 N (%) P Value
Conditioning regimen .003
Bu + Cy ± other 234 (17) 304 (20) 337 (22) 288 (18)
Cy + TBI ± other 1022 (72) 1118 (73) 1045 (69) 1129 (72)
TBI ± other 72 (5) 47 (3) 51 (3) 50 (3)
Other 86 (6) 72 (5) 84 (6) 92 (6)
GVHD prophylaxis .10
CsA + MTX ± other 713 (50) 777 (50) 783 (52) 770 (49)
Tacrolimus + MTX ±
other
300 (21) 356 (23) 342 (23) 404 (26)
T cell depletion ± other 279 (20) 289 (19) 263 (17) 259 (17)
CsA or tacrolimus ±
other
112 (8) 101 (6) 114 (7) 107 (7)
Other 10 (1) 18 (1) 14 (1) 19 (2)
Graft type .007
Bone marrow 1201 (85) 1262 (82) 1232 (81) 1251 (80)
Peripheral blood 213 (15) 279 (18) 285 (19) 308 (20)
Infused cell dose
BM >2108 744 (62) 748 (59) 756 (61) 786 (63) .63
BM #2108 445 (37) 501 (40) 466 (38) 456 (36)
BM missing 12 (1) 13 (1) 10 (1) 9 (1)
PB >5108 132 (62) 181 (65) 178 (62) 190 (62) .36
PB #5108 68 (32) 86 (31) 85 (30) 89 (29)
PB missing 13 (6) 12 (4) 22 (8) 29 (9)
Time from diagnosis to
transplant, median
(range), months
12 (2-309) 11 (1-309) 11 (2-242) 10 (<1-232) .04
Donor search time, median (range),
months
Diagnosis to preliminary
search
4 (<1-300) 3 (<1-303) 3 (<1-231) 3 (<1-192) .06
Preliminary search to
formal search
<1 (<1-69) <1 (<1-77) <1 (<1-116) <1 (<1-106) .33
Formal search to
transplant
3 (<1-81) 3 (<1-94) 3 (<1-121) 3 (<1-125) .81
Follow-up of survivors,
median (range), months
60 (5-133) 60 (5-135) 69 (3-138) 64 (3-137) <.001
AML indciates acute myelogenous leukemia; ALL, acute lymphoblastic leukemia; MDS, myelodysplastic syndrome; CML, chronic myelogenous leukemia;
HLA, human leukocyte antigen; CMV, cytomegalovirus; Cy, cyclophosphamide; Bu, busulfan; TBI, total body radiation; CsA, cyclosporine; MTX, meth-
otrexate; GVHD, graft-versus-host disease; BM, bone marrow; PB, peripheral blood.
*Based on 2004 Census tract data linking income to residential ZIP code.
1550 Biol Blood Marrow Transplant 15:1543-1554, 2009K. S. Baker et al.that African-American patients with a myocardial in-
farction and heart failure receive less intensive and
poorer quality care Whites [42,43-45]. In a study of
Medicare beneficiaries, who are presumed to have no
financial obstacle to care, treatment and outcomes of
heart failure were similar among White and African-
American patients [46]. All of the patients in our studyFigure 1. Probability of OS by race.received HCT, so, therefore, they had access to high-
cost, technologically demanding care, although it is
unknown whether their overall insurance coverage
was similar. Despite this, survival was lower in those
with the lowest income, even after adjustment for
race and measured comorbidities, and the excess mor-
tality was treatment related. It is still possible though
that reduced access to or utilization of post-HCT fol-
low-up care might contribute to the inferior outcomes
seen in our study.
The mechanism for the excess mortality seen in
African-American recipients seems likely to be com-
plex. Additional contributors may include unmeasured
comorbidities such as poor nutrition, inability to com-
ply with medication regimens, and poor access to
follow-up care. In addition, the National Health and
Nutrition Examination Survey reports increased fre-
quency of high blood pressure, high body mass index,
physical inactivity, and diabetes in African American
women, all of which, as unmeasured comorbidities,
might contribute to increased late mortality after
Figure 2. Cumulative incidence of TRM by race.
Figure 3. Probability of OS by income.
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challenging, as some are societal rather than medical
issues.However, awareness of the problem is an impor-
tant first step, so that care providers can consider the is-
sues and perhaps provide specific resources for this
high-risk population after leaving the transplant center.
Similar to the findings in our study, low SES, as-
sessed independently of race, has been reported to
have an adverse impact on outcomes of many diseases,
including cancer, chronic renal disease, and solid or-
gan transplantation [38,48,49]. Mackillop et al. [50]
studied the impact of SES on outcome of treatment
of cancer in Ontario, Canada, where the heath system
is designed to provide equitable access to health care
for all. Their study demonstrated higher mortality
rates from cancer among poorer communities com-
pared with wealthier areas. Recipients of renal and
liver transplants with private insurance have been re-
ported to have better survival than Medicare recipi-
ents, but SES measured by census tract was not
associated with outcome [51]. The difference in these
observations may reflect the dominant influence of
the quality of the surgical procedure and inpatient hos-Table 4. Multivariate Analysis for Overall Survival, Disease-Free S
Variable Overall Survival Disease-Free Su
Race
White† 1.00 1.00
African American 1.47 (1.29-1.68)§ 1.48 (1.30-1.6
Asian/Pacific-Islander 0.96 (0.76-1.20) 1.04 (0.83-1.3
Hispanic 1.15 (1.01-1.30) 1.14 (1.00-1.2
Income‡
>$56,300† 1.00 1.00
$43,600-56,300 1.06 (0.97-1.16) 1.03 (0.94-1.1
$34,700-43,600 1.06 (0.97-1.16) 1.02 (0.93-1.1
<$34,700 1.15 (1.04-1.26)§ 1.12 (1.01-1.2
Missing 1.10 (0.86-1.39) 1.08 (0.85-1.3
*Models were stratified on Karnofsky performance status prior to hematopo
†Reference group; Table 2 lists variables tested in multivariate analysis.
‡Based on 2004 Census data linking income to residential ZIP code.
§P < .01.pital care on long-term outcomes of solid organ trans-
plantation, in contrast to HCT where the period of
immune reconstitution is long (lasting months to
years) and the incidence of late mortality after the pa-
tient has left the transplant center is significant [51].
Clearly, low SES has a significant negative impact on
the unrelated donor HCT outcomes and transplant
centers need to carefully examine and optimize the
resources available to these individuals during the
peri-HCT time period as well as during ongoing
long-term follow-up.
Despite the large size of this study and the mean-
ingful cohorts of racial minority groups, there are lim-
itations that should be considered. Our study only
included patients who actually received HCT, and
thus we could not address the impact of race or SES
on access to transplantation. A challenge for our study,
in commonwith all studies of race, is a lack of precision
in the definition of race. In our study, race was re-
ported by the transplant center, and may not reflect
accurately persons of mixed heritage. Although the
relative proportions of minority racial groups in this
study do not match that of the U.S. population, weurvival, Relapse, and Treatment-Related Mortality
Relative risk
(95% Confidence Intervals)*
rvival Relapse Transplant-Related Mortality
1.00 1.00
9)§ 1.32 (1.03-1.68) 1.56 (1.34-1.83)§
1) 1.13 (0.80-1.61) 0.99 (0.75-1.32)
9) 0.87 (0.70-1.09) 1.30 (1.11-1.51)§
1.00 1.00
3) 0.94 (0.81-1.10) 1.11 (0.99-1.24)
2) 0.97 (0.83-1.13) 1.11 (0.99-1.24)
3) 1.07 (0.92-1.26) 1.21 (1.07-1.36)§
8) 0.97 (0.63-1.48) 1.16 (0.87-1.55)
ietic cell transplant.
Figure 4. Cumulative incidence of TRM by income.
1552 Biol Blood Marrow Transplant 15:1543-1554, 2009K. S. Baker et al.feel this is less of an issue related to access to care, or to
misclassification of race, but rather because of the fact
that minorities are underrepresented in the unrelated
donor pool making it more difficult to obtain a donor
for minority patients. Additionally, cancer incidence
rates for acute leukemia have been shown to vary by
race with a higher incidence being found in Whites
compared to Blacks [52]. Also, we do not have
data to reflect the insurance status of patients repre-
sented in the study, and our study could not address
other important factors that may have an impact on
access to transplant and access to and quality of post-
transplant care. Some of these factors, for instance, in-
surance coverage, lack of adequate support services,
and cultural biases, are potentially modifiable. In addi-
tion, socioeconomic status was estimated from zip
code of residence and was not self-reported by pa-
tients. Despite these limitations, we believe our dataTable 5. Important Causes of Death by Race and Socioeconomic S
Variable Total Deaths Relapse
Causes of death <100 days
Race
White 1531 167 (11%)
African American 147 10 (7%)
Asian/Pacific-Islander 51 2 (4%)
Hispanic 139 8 (6%)
Income
>$56,300 417 47 (11%)
$43,600-56,300 438 43 (10%)
$34,700-43,600 458 44 (10%)
<$34,700 490 50 (10%)
Causes of death $100 days
Race
White 1969 735 (37%)
African American 132 40 (30%)
Asian/Pacific-Islander 46 21 (46%)
Hispanic 174 60 (35%)
Income
>$56,300 550 213 (39%)
$43,600-56,300 580 207 (36%)
$34,700-43,600 598 221 (37%)
< $34,700 528 193 (37%)
*GVHD indicates graft-versus-host disease. Includes patients with cause of deindicate importantly inferior outcomes in African-
American unrelated donor HCT recipients that are
not explicable by reduced family income, and should
lead to future biologic, sociologic and epidemiologic
studies to address and improve this disparity. In addi-
tion, we show that reduced family income reduced
survival in recipients of all races, indicating the need
for careful support and follow-up of such patients.ACKNOWLEDGMENTS
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